- Home
- CTMX vs YSXT Comparison
CTMX vs YSXT Comparison
Compare CTMX & YSXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- YSXT
- Stock Information
- Founded
- CTMX 2008
- YSXT 2011
- Country
- CTMX United States
- YSXT China
- Employees
- CTMX N/A
- YSXT N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- YSXT Automotive Aftermarket
- Sector
- CTMX Health Care
- YSXT Consumer Discretionary
- Exchange
- CTMX Nasdaq
- YSXT Nasdaq
- Market Cap
- CTMX 444.3M
- YSXT 127.7M
- IPO Year
- CTMX 2015
- YSXT 2024
- Fundamental
- Price
- CTMX $2.41
- YSXT $5.45
- Analyst Decision
- CTMX Strong Buy
- YSXT
- Analyst Count
- CTMX 2
- YSXT 0
- Target Price
- CTMX $5.00
- YSXT N/A
- AVG Volume (30 Days)
- CTMX 2.6M
- YSXT 371.8K
- Earning Date
- CTMX 08-07-2025
- YSXT 08-15-2025
- Dividend Yield
- CTMX N/A
- YSXT N/A
- EPS Growth
- CTMX 128.27
- YSXT N/A
- EPS
- CTMX 0.49
- YSXT 0.18
- Revenue
- CTMX $147,557,000.00
- YSXT $66,143,276.00
- Revenue This Year
- CTMX N/A
- YSXT N/A
- Revenue Next Year
- CTMX N/A
- YSXT N/A
- P/E Ratio
- CTMX $5.15
- YSXT $29.71
- Revenue Growth
- CTMX 23.81
- YSXT 21.23
- 52 Week Low
- CTMX $0.40
- YSXT $2.06
- 52 Week High
- CTMX $3.10
- YSXT $9.96
- Technical
- Relative Strength Index (RSI)
- CTMX 57.13
- YSXT N/A
- Support Level
- CTMX $2.15
- YSXT N/A
- Resistance Level
- CTMX $2.44
- YSXT N/A
- Average True Range (ATR)
- CTMX 0.22
- YSXT 0.00
- MACD
- CTMX -0.03
- YSXT 0.00
- Stochastic Oscillator
- CTMX 41.67
- YSXT 0.00
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.